Home   |   About Journal   |   Editorial Board   |   Instruction   |   Subscriptions   |   Contacts Us   |   中文
journal1  2023, Vol. 43 Issue (2): 127-129    DOI: 10.3969/j.issn.1001-8131.2023.02.047
Current Issue | Archive | Adv Search |
Research Progress on the Immunoregulatory Role of CD155 in Malignant Tumors
Liu Xue1, Guo Lingchuan2
1. Department of Oncology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu,China;
2. Department of Pathology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu,China
Download: PDF (487 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  CD155,a glycoprotein of immunoglobulin superfamily,is up-regulated in a variety of malignant tumor cells and associated with patient prognosis.Recently,the immunoregulatory role of CD155 has attracted extensive attention in tumors.CD155 could interact with co-stimulatory receptors(CD226)and co-inhibitory receptors(TIGIT and CD96),regulating function of tumor infiltrating lymphocytes.Immunotherapy of targeting CD155 signaling is expected to improve the prognosis of tumor patients and has great potential for clinical application.This article will review the research progress of CD155 from the aspects of the relationship between CD155 and the prognosis of malignant tumor patients,immunoregulatory role and related immunotherapy.
Key wordsCD155      CD226      TIGIT      CD96      malignant tumors      immunotherapy     
Received: 06 May 2022     
PACS:  R730.4  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Liu Xue
Guo Lingchuan
Cite this article:   
Liu Xue,Guo Lingchuan. Research Progress on the Immunoregulatory Role of CD155 in Malignant Tumors[J]. journal1, 2023, 43(2): 127-129.
URL:  
http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2023.02.047     OR     http://www.hrbyybjb.org.cn/EN/Y2023/V43/I2/127
Copyright © Editorial Board of journal1
Supported by:Beijing Magtech